Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1478852rdf:typepubmed:Citationlld:pubmed
pubmed-article:1478852lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0596901lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0075455lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:1478852lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:1478852pubmed:issue3lld:pubmed
pubmed-article:1478852pubmed:dateCreated1993-2-11lld:pubmed
pubmed-article:1478852pubmed:abstractTextSuccinylacetone (SA) proved to be a potent inhibitor of in vitro lymphoproliferative responses. This compound (3.0 mM) reduced the incorporation of 3HTdr by > 90% in mononuclear cell cultures stimulated with PHA, anti-CD3, IL-2 or phorbol dibutyrate-Ca2+ ionomycin. Furthermore, SA caused profound reduction in isotope uptake even if added to 3-day PHA-stimulated cultures as late as 6 h prior to harvest. Cells exposed to SA prior to mitogenic challenge and washed were not impaired in their proliferative activities. The addition of hematin to SA-containing cultures did not reverse the proliferative block. Phenotypic studies of stimulated cells suggested that SA does not preferentially affect one functional group of lymphocytes. However, it appeared that SA may act selectively to inhibit expression of transferrin receptors (CD71), a T-cell activation antigen. These data suggest that SA acts as a noncytotoxic immune inhibitor; this activity may be mediated, in part, by blocking cell activation and subsequent progress through the mitotic cycle.lld:pubmed
pubmed-article:1478852pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:languageenglld:pubmed
pubmed-article:1478852pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:citationSubsetIMlld:pubmed
pubmed-article:1478852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1478852pubmed:statusMEDLINElld:pubmed
pubmed-article:1478852pubmed:issn0162-3109lld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:JacksonM OMOlld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:HessR ARAlld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:BlaeseR MRMlld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:WinkelsteinAAlld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:WeaverL DLDlld:pubmed
pubmed-article:1478852pubmed:authorpubmed-author:LeichtlingK...lld:pubmed
pubmed-article:1478852pubmed:issnTypePrintlld:pubmed
pubmed-article:1478852pubmed:volume24lld:pubmed
pubmed-article:1478852pubmed:ownerNLMlld:pubmed
pubmed-article:1478852pubmed:authorsCompleteYlld:pubmed
pubmed-article:1478852pubmed:pagination161-70lld:pubmed
pubmed-article:1478852pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:meshHeadingpubmed-meshheading:1478852-...lld:pubmed
pubmed-article:1478852pubmed:articleTitleInhibition of human lymphoproliferative responses and altered lymphocyte membrane phenotype by succinylacetone.lld:pubmed
pubmed-article:1478852pubmed:affiliationDepartment of Medicine, University of Pittsburgh School of Medicine, PA.lld:pubmed
pubmed-article:1478852pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1478852pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1478852lld:pubmed